Biotheus Inc. has entered into a license and collaboration agreement with Hansoh Pharmaceuticals (Hansoh Pharmaceutical Group Co. Ltd.) for Biotheus' EGFR/MET bispecific antibody PM-1080 in Greater China, including mainland China, Hong Kong, Macao and Taiwan.
Que Oncology Inc.’s Q-122 significantly reduced the frequency and severity of moderate and severe vasomotor symptoms, or hot flashes, in women taking endocrine therapy for breast cancer, and phase II results showed associated improvement in quality of life, compared with placebo.
New and updated preclinical and clinical data presented by biopharma firms at the Society for Immunotherapy of Cancer Annual Meeting including: Adagene, Agenus, Aim, Alligator, Candel, Carisma, Cellectis, Corbus, Evolveimmune, Hotspot, Imcheck, Immunome, Immutep, Kalivir, Marengo, Medicenna, Myeloid, Nanobiotix, Nektar, Nutcracker, Nurix, Oncolytics, Onconano, Pact, Portage, Rigel, Scholar Rock, Seagen, Sotio, Triumvira, Vaccinex, Xencor.
Researchers from Totus Medicines Inc. presented preclinical data for the potent and selective covalent inhibitor of phosphoinositide 3-kinase α (PI3Kα), TOS-358, which is being developed for the treatment of cancer.
Researchers from Black Diamond Therapeutics Inc. presented the discovery and preclinical characterization of a novel brain-penetrant BRAF class I/II/III mutation inhibitor, BDTX-4933.
RSS
